Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe SepsisEdward Abraham, Abla A. Creasey, Pierre François Laterre et al.|JAMA|2003Cited by 958
Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.Abla A. Creasey, L. B. Hinshaw|Journal of Clinical Investigation|1993Cited by 552
The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsisSteven M. Opal, Abla A. Creasey, BA John E. Palardy et al.|Critical Care Medicine|2001Cited by 68
A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumoniaPierre-François Laterre, Richard G. Wunderink, Steven M. Opal et al.|Critical Care|2009Cited by 45